---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-030780"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:23:13.022887+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Vanda Pharma discloses 2024 bonuses, 2025 salaries, and RSU grants for NEOs

## Summary
- CEO Polymeropoulos: 2024 bonus $947,928; 2025 base salary $965,655; target bonus 80%; 450,000 RSUs.
- CFO Moran and three SVPs: 2024 bonuses $309,181–$320,040; 2025 base $559,935–$579,600; 45% target; 125,000 RSUs each.
- All RSUs vest in four equal annual installments commencing March 1, 2026.
- Compensation Committee considered peer-group analysis by Willis Towers Watson before approving.

## SEC filing metadata
- accession: 0001193125-25-030780
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/0001193125-25-030780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/d935984d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-030780
- JSON: https://secwatch.observer/filing/0001193125-25-030780.json
- Plain text: https://secwatch.observer/filing/0001193125-25-030780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.